What this means
This trial plans to test whether a high-dose flu shot gives stronger antibody levels than a standard shot. It has not started recruiting, so it does not yet show whether either shot works better.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 60 and over
- Where
- 1 site
The science
- Registered title
- Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore
- Trial ID
- NCT07883421 ↗
- Phase
- PHASE 4
- Study type
- interventional
- Conditions
- Influenza
- What is tested
- High-dose influenza vaccine, Standard-dose influenza vaccine
- Sponsor
- Tan Tock Seng Hospital
- Ages
- 60 Years to no maximum
- Dates
- First posted Oct 20, 2026 · updated Oct 20, 2026
Registry summary
The goal of this clinical trial is to learn if the high-dose influenza vaccine can improve year-round protection in older adults aged 60 years and above. The main question it aims to answer is:
- Can the high-dose influenza vaccine induce higher antibody titres at Day 14 post-vaccination compared to standard-dose influenza vaccine?
Participants will:
- Receive one dose of either the high-dose or standard-dose influenza vaccine
- Be followed for one year, with four scheduled visits
- Keep a diary of their symptoms for 3 days after vaccination
- Report symptoms whenever they experience an acute respiratory infection (ARI), self-perform lateral flow assay (LFA) testing capable of detecting influenza A and B, and send nasal swabs for central testing
Sites (1)
- National Centre for Infectious Diseases (NCID), Singapore, Singapore